Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)vsScienture Holdings, Inc. (SCNX)
HKPD
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
$0.66
+4.60%
HEALTHCARE · Cap: $6.99M
SCNX
Scienture Holdings, Inc.
$0.46
-5.08%
HEALTHCARE · Cap: $19.69M
Smart Verdict
WallStSmart Research — data-driven comparison
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares generates 3009% more annual revenue ($20.31M vs $653,390). SCNX leads profitability with a 0.0% profit margin vs -0.1%. HKPD earns a higher WallStSmart Score of 36/100 (F).
HKPD
Hold36
out of 100
Grade: F
SCNX
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HKPD.
Margin of Safety
+91.2%
Fair Value
$5.10
Current Price
$0.46
$4.64 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 130.2% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
ROE of -0.6% — below average capital efficiency
Revenue declined 4.7%
Negative free cash flow — burning cash
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -24.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HKPD
The strongest argument for HKPD centers on Price/Book, EPS Growth.
Bull Case : SCNX
The strongest argument for SCNX centers on P/E Ratio, Price/Book.
Bear Case : HKPD
The primary concerns for HKPD are Market Cap, Return on Equity, Revenue Growth.
Bear Case : SCNX
The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
HKPD profiles as a turnaround stock while SCNX is a value play — different risk/reward profiles.
SCNX is growing revenue faster at 8.1% — sustainability is the question.
HKPD generates stronger free cash flow (-106,393), providing more financial flexibility.
Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HKPD scores higher overall (36/100 vs 33/100). SCNX offers better value entry with a 91.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Hong Kong Pharma Digital Technology Holdings Limited is a pioneering company at the intersection of biotechnology and digital healthcare, focusing on the integration of cutting-edge technology with pharmaceutical services to enhance patient outcomes and streamline healthcare delivery. Leveraging advanced digital solutions and data analytics, the company optimizes drug development processes and improves operational efficiencies, positioning itself as a critical player in the evolving healthcare landscape. With a strong commitment to health technology advancement and the cultivation of strategic alliances, Hong Kong Pharma is poised to meet the demands of both domestic and global markets while driving innovation across its pharmaceutical service offerings.
Scienture Holdings, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Scienture Holdings, Inc. (SCNX) is an innovative biotechnology company focused on developing cutting-edge therapeutic solutions for neurological disorders. With a robust drug development pipeline supported by advanced technology and a highly skilled research team, Scienture is committed to meeting unmet medical needs and improving patient outcomes. The company's strategic emphasis on scientific excellence, regulatory compliance, and collaborative partnerships positions it well for growth within the burgeoning healthcare sector, highlighting its potential to make significant contributions to global health advancements.
Compare with Other PHARMACEUTICAL RETAILERS Stocks
Want to dig deeper into these stocks?